RecruitingPhase 1NCT07493512

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer

Sponsor

Amgen

Enrollment

40 participants

Start Date

Apr 28, 2026

Study Type

INTERVENTIONAL

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Summary

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Xaluritamig for people with metastatic castration-resistant prostate cancer (mcrpc). The study is currently recruiting participants at 5 locations. People eligible for this study include men aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXaluritamig

Participants will receive xaluritamig via short-term intravenous (IV) infusion.

Locations(10)

Rocky Mountain Cancer Centers

Denver, Colorado, United States

United States Oncology Regulatory Affairs Corporate Office

Denver, Colorado, United States

US Oncology Research Investigational Products Center

Denver, Colorado, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Sanford Oncology Clinic and Pharmacy

Sioux Falls, South Dakota, United States

Sarah Cannon Research Institute Oncology Partners

Nashville, Tennessee, United States

Next Oncology - Dallas

Irving, Texas, United States

Chris OBrien Lifehouse

Camperdown, New South Wales, Australia

Monash Medical Centre

Clayton, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07493512

Related Trials

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT0346097782 locations

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650329 locations

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

NCT075709793 locations

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

NCT0397265724 locations

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

NCT0710301813 locations